Table:
|  | Fiscal Years Ended March 31, |  |
| --- | --- | --- |
|  | 2018 (1) | 2017 (2) |
| Pro forma revenues (3) | $1,217,655 | $1,060,777 |
| Pro forma net income from continuing operations available to common stockholders (3) | 51,975 | 226,086 |
| Pro forma earnings per common share - basic (3) | 0.98 | 4.86 |
| Pro forma earnings per common share - diluted (3) | 0.89 | 4.08 |
| Pro forma common shares - basic | 52,798 | 46,552 |
| Pro forma common shares - diluted | 58,640 | 55,389 |
Paragraphs:
Pro Forma Results
The following table summarizes, on a pro forma basis, the combined results of operations of the Company and TOKIN as though the acquisition and the Sale of EMD had occurred as of April 1, 2016. The pro forma amounts presented are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of April 1, 2016, or of future consolidated operating results (amounts in thousands, except per share data):
(1) The net income for the fiscal year ended March 31, 2018 excludes the following: 34% of the gain on sale of the EMD business of $75.2 million, the gain related to the fair value of KEMET’s previous 34% interest in TOKIN of $68.7 million, and the bargain gain on the acquisition of TOKIN of $62.2 million.
(2) The net income for the fiscal year ended March 31, 2017 includes the following: 34% of the gain on sale of the EMD business of $123.4 million (which includes the release of a valuation allowance that was recorded in the fourth quarter of fiscal year 2017 and the use of the deferred tax asset which was recorded in the first quarter of fiscal year 2018), the gain related to the fair value of KEMET’s previous 34% interest in TOKIN of $66.7 million, and the bargain gain on the acquisition of TOKIN of $60.3 million.
(3) Fiscal years ended March 31, 2018 and 2017 adjusted due to the adoption of ASC 606.
Question:
What was the percentage change in the diluted Pro forma common shares between 2017 and 2018?
Answer: (58640-55389)/55389 = 5.87